Madam Speaker, I have listened to the debate so far from various members. I have talked about access for rare disease patients being very important. There is a University of Ottawa study from the IFSD Institute, which is where the former Parliamentary Budget Officer, Kevin Page, went. It did a study on what pharmacare would cost and what the different implications would be. It took some of the Hoskins report, some of the underlying variables, and it estimated that we would have to raise the GST by 2% across all of Canada in order to finance this pharmacare system.
Does the member agree with that assessment? If he does not agree with it, will he then commit not to raise a single extra dollar in taxes on hard-working Canadians to pay for the national pharmacare system that will not work for rare disease patients?